Cas no 392323-63-6 (4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide)

4-[(3,5-Dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide is a sulfonamide-based compound featuring a benzamide core substituted with a 3,5-dimethylpiperidine sulfonyl group and a morpholine moiety. This structure confers potential utility in medicinal chemistry, particularly as an intermediate for biologically active molecules. The presence of the sulfonyl group enhances binding affinity to target proteins, while the morpholine and dimethylpiperidine substituents contribute to improved solubility and pharmacokinetic properties. Its well-defined molecular architecture makes it suitable for structure-activity relationship (SAR) studies in drug discovery. The compound is typically synthesized under controlled conditions to ensure high purity and consistency, making it a reliable choice for research applications.
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide structure
392323-63-6 structure
Product Name:4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
CAS No:392323-63-6
MF:C18H27N3O4S
MW:381.489683389664
CID:5771189
PubChem ID:4063195
Update Time:2025-06-08

4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide Chemical and Physical Properties

Names and Identifiers

    • 4-(3,5-dimethylpiperidin-1-yl)sulfonyl-N-morpholin-4-ylbenzamide
    • SMR000324444
    • CHEMBL1416197
    • Oprea1_563359
    • VU0493895-1
    • MLS000680187
    • HMS1649N07
    • 4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
    • HMS2595O07
    • HMS3381P17
    • 392323-63-6
    • AKOS024577698
    • F0440-0258
    • 4-((3,5-dimethylpiperidin-1-yl)sulfonyl)-N-morpholinobenzamide
    • Benzamide, 4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]-N-4-morpholinyl-
    • Inchi： 1S/C18H27N3O4S/c1-14-11-15(2)13-21(12-14)26(23,24)17-5-3-16(4-6-17)18(22)19-20-7-9-25-10-8-20/h3-6,14-15H,7-13H2,1-2H3,(H,19,22)
    • InChI Key： NSQDLKQAMCSIIX-UHFFFAOYSA-N
    • SMILES： S(C1C=CC(C(NN2CCOCC2)=O)=CC=1)(N1CC(C)CC(C)C1)(=O)=O

Computed Properties

  • Exact Mass: 381.17222752g/mol
  • Monoisotopic Mass: 381.17222752g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 6
  • Heavy Atom Count: 26
  • Rotatable Bond Count: 4
  • Complexity: 568
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 2
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 1.9
  • Topological Polar Surface Area: 87.3?2

Experimental Properties

  • Density: 1.30±0.1 g/cm3(Predicted)
  • pka: 11.37±0.20(Predicted)

4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Life Chemicals
F0440-0258-2μmol
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
2μl
 $57.0 2023-05-17
Life Chemicals
F0440-0258-5μmol
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
5μl
 $63.0 2023-05-17
Life Chemicals
F0440-0258-10μmol
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
10μl
 $69.0 2023-05-17
Life Chemicals
F0440-0258-20μmol
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
20μl
 $79.0 2023-05-17
Life Chemicals
F0440-0258-1mg
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
1mg
 $54.0 2023-05-17
Life Chemicals
F0440-0258-2mg
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
2mg
 $59.0 2023-05-17
Life Chemicals
F0440-0258-3mg
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
3mg
 $63.0 2023-05-17
Life Chemicals
F0440-0258-4mg
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
4mg
 $66.0 2023-05-17
Life Chemicals
F0440-0258-5mg
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
5mg
 $69.0 2023-05-17
Life Chemicals
F0440-0258-10mg
4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide
 392323-63-6 90%+
10mg
 $79.0 2023-05-17

4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide Related Literature

Additional information on 4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide

Research Brief on 4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide (CAS: 392323-63-6)

The compound 4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide (CAS: 392323-63-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential as a drug candidate.

Recent studies have highlighted the role of 4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide as a potent inhibitor of specific protein-protein interactions (PPIs) involved in cancer progression. The compound's unique structural features, including the sulfonyl and morpholine moieties, contribute to its high binding affinity and selectivity. Computational docking studies have revealed that it targets the p53-MDM2 interaction, a critical pathway in tumor suppression, with an IC50 value in the nanomolar range.

In vitro assays conducted on various cancer cell lines, including MCF-7 (breast cancer) and A549 (lung cancer), demonstrated significant antiproliferative effects. The compound induced apoptosis via caspase-3 activation and inhibited cell migration, suggesting its potential as a dual-action therapeutic agent. Furthermore, pharmacokinetic studies in rodent models indicated favorable bioavailability and low toxicity, supporting its candidacy for further preclinical development.

Despite these promising results, challenges remain in optimizing the compound's metabolic stability and solubility. Recent efforts have focused on structural modifications, such as introducing polar substituents, to enhance its drug-like properties. Collaborative research between academia and industry is underway to advance this molecule into clinical trials, with preliminary data expected in the next 12-18 months.

In conclusion, 4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide represents a promising scaffold for anticancer drug development. Its mechanism of action, combined with encouraging preclinical data, positions it as a compelling candidate for further investigation. Future studies should address formulation challenges and explore combination therapies to maximize its therapeutic potential.

392323-63-6 (4-[(3,5-dimethylpiperidin-1-yl)sulfonyl]-N-(morpholin-4-yl)benzamide) Related Products

Recommended suppliers
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Wuhan Comings Biotechnology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Wuhan Comings Biotechnology Co., Ltd.
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.
Shandong Jing Kun Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Jing Kun Chemical Co.,Ltd.
Shanghai Jinhuan Chemical CO., LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shanghai Jinhuan Chemical CO., LTD.